BRIEF-Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program
November 24, 2017 at 06:21 AM EST
* Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs
